STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

[SCHEDULE 13G/A] Soleno Therapeutics, Inc. SEC Filing

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
SCHEDULE 13G/A

Rhea-AI Filing Summary

Soleno Therapeutics, Inc. Schedule 13G/A reports that Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, may be deemed beneficial owners of 1,001,350 shares of Soleno common stock as of June 30, 2025. That holding represents 1.99% of the class. The filing states the shares are held by funds and separately managed accounts under Nantahala’s control and that the positions were acquired and are held in the ordinary course of business, not to influence control.

Positive

  • Full disclosure of beneficial ownership: 1,001,350 shares reported for Nantahala and its managing members
  • Transparent classification as an investment adviser (IA) and statement that holdings are held in the ordinary course

Negative

  • Holding is only 1.99% of the class, below the 5% threshold that typically signals material influence or activist potential

Insights

TL;DR Nantahala reports a small, disclosed 1.99% stake in SLNO, a non-controlling position held in the ordinary course.

The filing documents a clear, verifiable economic exposure of 1,001,350 shares representing 1.99% of Soleno's outstanding common stock. Because the stake is below 5% and the reporting persons assert the position is held in the ordinary course and not for control, the direct market impact is likely limited. The filing enhances transparency about institutional ownership but does not indicate activist intent or governance change.

TL;DR Disclosure confirms beneficial ownership but shows no control signals or group formation; governance impact appears minimal.

The Schedule 13G/A classifies Nantahala as an investment adviser and lists shared voting and dispositive power over the disclosed shares for both named managing members. The report explicitly notes no sole voting or dispositive power and that the position is not held to influence control. From a governance perspective, this is routine institutional reporting without indications of coordinated action or control ambitions.






Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Rule 13d-1(b)
Rule 13d-1(c)
Rule 13d-1(d)






SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G





SCHEDULE 13G



Nantahala Capital Management, LLC
Signature:/s/ Taki Vasilakis
Name/Title:Taki Vasilakis / Chief Compliance Officer
Date:08/14/2025
Wilmot B. Harkey
Signature:/s/ Wilmot B. Harkey
Name/Title:Wilmot B. Harkey
Date:08/14/2025
Daniel Mack
Signature:/s/ Daniel Mack
Name/Title:Daniel Mack
Date:08/14/2025

FAQ

How many Soleno (SLNO) shares does Nantahala Capital Management report owning?

The filing reports 1,001,350 shares beneficially owned by Nantahala and its managing members.

What percentage of SLNO does the reported holding represent?

The reported position represents 1.99% of the outstanding common stock as of June 30, 2025.

Are the reporting persons claiming control of Soleno (SLNO)?

No. The filing states the shares are held in the ordinary course of business and not for the purpose of changing or influencing control.

Who filed the Schedule 13G/A for SLNO?

The filing was made by Nantahala Capital Management, LLC and co-filed by managing members Wilmot B. Harkey and Daniel Mack.

What voting and dispositive power is reported for the shares?

The filing reports 0 shares with sole voting or dispositive power and 1,001,350 shares with shared voting and shared dispositive power.
Soleno Therapeutics Inc

NASDAQ:SLNO

SLNO Rankings

SLNO Latest News

SLNO Latest SEC Filings

SLNO Stock Data

2.42B
52.69M
1.79%
110.24%
14.27%
Biotechnology
Pharmaceutical Preparations
Link
United States
REDWOOD CITY